ArticleBritish journal of cancer2016
Risk of venous thromboembolism in people with lung cancer: a cohort study using linked UK healthcare data.
Article in British journal of cancer, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Risk factors for postoperative venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.Frontiers in medicine · 2025Pooled it
- Non-bacterial Thrombotic Endocarditis in Lung Cancer: A Systematic Review.Current cardiology reviews · 2025Pooled it
- Incidence and risk factors of VTE in lung cancer: a meta-analysis.Annals of medicine · 2024Pooled it
- Prevalence and clinical characteristics of venous thromboembolism in patients with lung cancer: a systematic review and meta-analysis.Frontiers in oncology · 2024Pooled it
- Can thromboprophylaxis build a link for cancer patients undergoing surgical and/or chemotherapy treatment? The MeTHOS cohort study.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2022Trial
- Khorana Score: Νew Predictor of Early Mortality in Patients With Lung Adenocarcinoma.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis · 2018Trial
- Trial
- Risk Factors for Developing Venous Thromboembolism in Patients With Advanced ALK-Rearranged NSCLC.JTO clinical and research reports · 2026Article
- Clinical Characteristics and Prognosis of Thromboembolism in Elderly Patients With Stage IV Lung Cancer.Geriatrics & gerontology international · 2026Article
- Enhanced protein carbonylation is associated with prolonged fibrin clot lysis in patients with advanced lung cancer: impact on long-term mortality.Journal of thoracic disease · 2025Article
- Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis.Frontiers in oncology · 2025Article
- Development and validation of a nomogram model for predicting venous thromboembolism risk in lung cancer patients treated with immune checkpoint inhibitors: A cohort study in China.Cancer medicine · 2024Article
- Review
- Tumor-infiltrating platelets promote the growth of lung adenocarcinoma.Translational oncology · 2024Article
- Role of recombinant human granulocyte colony-stimulating factor in development of cancer-associated venous thromboembolism in lung cancer patients who undergo chemotherapy.Frontiers in immunology · 2024Article
- Management of venous thromboembolism in patients with lung cancer: a state-of-the-art review.BMJ open respiratory research · 2023Review
- Osimertinib for an Advanced NSCLC Patient with Two Common EGFR Mutations and a Concomitant MET Exon 14 Skipping Mutation: A Case Report.Cancer management and research · 2023Article
- Stratification of Risk Factors of Lung Cancer-Associated Venous Thromboembolism and Determining the Critical Point for Preemptive Intervention: A Systematic Review With Meta-analysis.Clinical Medicine Insights. Oncology · 2023Review
- Resveratrol Affects Sphingolipid Metabolism in A549 Lung Adenocarcinoma Cells.International journal of molecular sciences · 2022Article
- One-Year Incidences of Venous Thromboembolism, Bleeding, and Death in Patients With Lung Cancer (Cancer-VTE Subanalysis).JTO clinical and research reports · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
6 authors.
Funding
Abstract
backgroundVenous thromboembolism (VTE) is a potentially preventable cause of death in people with lung cancer. Identification of those most at risk and high-risk periods may provide the opportunity for better targeted intervention.
methodsWe conducted a cohort study using the Clinical Practice Research Datalink linked to Hospital Episode Statistics and Cancer Registry data. Our cohort comprises 10 598 people with lung cancer diagnosed between 1997 and 2006 with follow-up continuing to the end of 2010. Cox regression analysis was performed to determine which demographic, tumour and treatment-related factors (time-varying effects of chemotherapy and surgery) independently affected VTE risk. We also determined the effect of a VTE diagnosis on the survival of people with lung cancer.
resultsPeople with lung cancer had an overall VTE incidence of 39.2 per 1000 person-years (95% confidence interval (CI), 35.4-43.5), though rates varied depending on the patient group and treatment course. Independent factors associated with increased VTE risk were metastatic disease (hazard ratio (HR)=1.9, CI 1.2-3.0 vs local disease); adenocarcinoma subtype (HR=2.0, CI 1.5-2.7, vs squamous cell; chemotherapy administration (HR=2.1, CI 1.4-3.0 vs outside chemotherapy courses); and diagnosis via emergency hospital admission (HR=1.7, CI 1.2-2.3 vs other routes to diagnosis). Patients with VTE had an approximately 50% higher risk of mortality than those without VTE.
conclusionsPeople with lung cancer have especially high risk of VTE if they have advanced disease, adenocarcinoma or are undergoing chemotherapy. The presence of VTE is an independent risk factor for death.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.